What happened
Shares of Eargo (NASDAQ: EAR), a hearing aid manufacturer, are sinking in response to the disclosure of a federal investigation the company made to investors after markets closed on Wednesday. The medical device stock was down 68.5% as of 10:40 a.m. EDT on Thursday.
So what
Eargo reported net revenue that rose 44% year over year to $23 million in the second quarter, but a recent SEC disclosure has investors questioning the integrity of the company's sales figures. On Sept. 21, Eargo was informed that it is the target of a criminal investigation by the U.S. Department of Justice.
Image source: Getty Images.
The investigation is related to insurance reimbursement claims the company submitted on behalf of customers covered by federal health plans. Eargo markets tiny rechargeable hearing aids that cost nearly $3,000 per pair.
In August, Eargo increased its revenue forecast for 2021 to a range between $93 million and $96 million. In light of the investigation, though, the company withdrew its financial guidance for the year.
Now what
Without a way to be sure sales to insurers can remain on the company's income statement, investment banks including J.P. Morgan and Wells Fargo severely lowered their ratings on the medical device start-up.
It's hard to guess how much of an impact the DOJ investigation will have without more details. We do know the company's largest third-party payor initiated a claims audit earlier this year. Intrepid investors thinking about catching this falling knife probably want to stand back until we know more.
10 stocks we like better than Eargo, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Eargo, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 17, 2021
Wells Fargo is an advertising partner of The Ascent, a Motley Fool company. JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
